**INTER-AGENCY TECHNICAL BRIEF**

Treatment of uncomplicated *P. falciparum* malaria in the first trimester of pregnancy: Implementation of the revised WHO treatment guidelines (25 November 2022)

# Table of contents

[Table of contents 1](#_Toc125538981)

[Abbreviations 1](#_Toc125538982)

[Summary 2](#_Toc125538983)

[Background 2](#_Toc125538984)

[New WHO recommendation on malaria case management in the first trimester of pregnancy 3](#_Toc125538985)

[Expected benefits 3](#_Toc125538986)

[Considerations for implementation of the new recommendation 4](#_Toc125538987)


[Rationale for this update 6](#_Toc125538988)

[Comparative data on the treatment of uncomplicated malaria with artemisinin antimalarials   
and quinine 6](#_Toc125538989)

[Annex 1. Frequently Asked Questions (FAQs) 10](#_Toc125538990)

[Annex 2. Number of confirmed exposed pregnancies for each artemisinin treatment type 12](#_Toc125538991)

[References 13](#_Toc125538992)



# Abbreviations

AAP artesunate+atovaquone-proguanil

ABTs artemisinin-based treatments

ACT artemisinin-based combination therapy

aHR adjusted Hazard Ratio

AL artemether-lumefantrine

ASAQ artesunate-amodiaquine

ASMQ artesunate-mefloquine

DHA-PQP dihydroartemisinin-piperaquine

G6PD glucose-6-phosphate dehydrogenase

IPD individual-patient data

IPTp intermittent preventive treatment in pregnancy

ITNs insecticide-treated nets

non-ABTs non-artemisinin-based treatments

PYR-AS pyronaridine-artesunate

SP sulfadoxine-pyrimethamine

WHO World Health Organization

# Summary

On 25th November 2022, the World Health Organization (WHO) updated the guidelines for the treatment of uncomplicated malaria in the first trimester to include artemether-lumefantrine as the preferred treatment option[[1]](#footnote-2). The recommendation was based on a review of the evidence on the safety of artemisinin-based treatments used in early pregnancy. An updated meta-analysis of prospective observational studies of pregnancies exposed to artemisinin and non-artemisinin antimalarials in the first trimester showed no evidence of teratogenicity or embryotoxicity based on the risk of miscarriage, stillbirth, or major congenital anomalies associated with artemisinin treatments. Pregnancies treated in the first trimester with artemether-lumefantrine, the artemisinin-based combination therapy (ACT) with most safety data available for the first trimester, had a 42% lower risk of adverse pregnancy outcomes than those treated with oral quinine. The safety data from this meta-analysis, together with the superior tolerability and better adherence, higher efficacy, longer duration of post-treatment prophylaxis, and wide availability of ACTs, is the basis for the WHO recommendation that artemether-lumefantrine is the preferred treatment for uncomplicated P. falciparum malaria in the first trimester of pregnancy. For countries where AL is not recommended or not available, other ACTs such as artesunate-amodiaquine (ASAQ), dihydroartemisinin-piperaquine (DHA-PPQ) or artesunate-mefloquine (ASMQ) can be used. All malaria-endemic countries are to consider updating their national treatment guidelines to implement the new recommendation to ensure all pregnant women are treated with the best possible treatment in the first trimester.

# Background

Malaria infection during pregnancy is a major public health problem, with the potential to cause severe maternal and fetal morbidity and mortality. Recent studies have shown that malaria in the first trimester induces maternal anaemia, fetal death, and fetal growth impairment, even when infections are subclinical.1 The World Health Organization (WHO) recommends a three-pronged approach to prevent the consequences of malaria in pregnancy including the provision of intermittent preventive treatment in pregnancy (IPTp) using sulfadoxine-pyrimethamine (SP), the use of insecticide-treated nets (ITNs), and appropriate case management through prompt and effective treatment of malaria in pregnant women.2 IPTp with SP is not recommended in the first trimester, i.e., before 13 weeks of gestation as the use of folate antagonists in the first trimester is associated with neural tube defects.3,4 Prompt and effective diagnosis and treatment of malaria infections in the first trimester of pregnancy is therefore particularly important, as is the use of ITNs to prevent infections. The WHO has recommended artemisinin-based combination therapies (ACTs) as first-line treatment for uncomplicated falciparum malaria in the general population since 2001, and in the second and third trimesters of pregnancy since 2006. Previously, quinine with or without clindamycin was recommended for the treatment of malaria in the first trimester, and ACTs were not recommended because of the embryotoxicity of artemisinin and its derivatives identified in animal studies unless no alternative treatment was available.5,6 Also, until now, there was limited information on safety following inadvertent exposures of pregnant women in the first trimester to ACTs, although ACTs are widely available in both public and private antimalarial retail markets.7,8 Observational studies have revealed that in practice, women in their first trimester were more likely to be treated with an ACT than with quinine in sub-Saharan Africa.9-12 This is because women may not know or declare they are pregnant at the time of seeking care, and healthcare providers do not always assess pregnancy status in women of reproductive age. Also, there is a lack of compliance to quinine + clindamycin treatment regimens by both health workers and pregnant women due to poor tolerability and the complex 7-day treatment regimen, and clindamycin is often unavailable.

In April 2022, WHO convened a Guideline Development Group meeting on malaria chemotherapy to develop new recommendations based on a review of new evidence on the safety of ACTs for treatment in the first trimester of pregnancy. This new evidence was based on an updated meta-analysis of safety data from documented human exposures in the first trimester from Asia and Africa (737 **artemisinin-based treatments** (ABTs) and 1,076 **non-artemisinin-based treatments** (non-ABTs). Results indicated that ABT exposure in the first trimester of pregnancy does not increase the risk of miscarriage, stillbirths or major congenital anomalies compared to non-ABTs including quinine.13 Furthermore, first-trimester treatment with artemether-lumefantrine (AL) was associated with significantly fewer (42% lower) adverse pregnancy outcomes than first-trimester oral quinine treatment. These data together with evidence of better efficacy, post-treatment prophylaxis, tolerability, and adherence in the second and third trimester of pregnancy14-16,17,18 indicate that **the 3-days, twice daily artemether-lumefantrine regimen, the ACT with the most safety evidence available, should replace the   
7-day, 8-hourly quinine regimen as the preferred treatment for uncomplicated** P. falciparum **malaria in the first trimester of pregnancy.**

Based on the updated review, **WHO has generated a strong recommendation on the treatment of uncomplicated malaria in the first trimester of pregnancy**19 and recommends national health authorities to implement the recommendation as part of their national treatment policies.

# New WHO recommendation on malaria case management in the first trimester of pregnancy (STRONG RECOMMENDATION, LOW CERTAINTY OF EVIDENCE)19

**Treat pregnant women with uncomplicated P. falciparum malaria with artemether-lumefantrine during the first trimester.**

* Limited exposures to other ACTs (artesunate-amodiaquine, artesunate-mefloquine and dihydroartemisinin-piperaquine) suggest that the current evidence is insufficient to make a recommendation for routine use of these other ACTs in the first trimester of pregnancy. However, consistent with the previous WHO recommendation that provided for limited use of ACTs if the first-line recommended medicine was not available, these other ACTs may be considered for use where artemether-lumefantrine is not a recommended ACT for uncomplicated malaria or is not available, given the demonstrated poorer outcomes of quinine treatment, along with the challenges of adherence to a seven-day course of treatment.
* Antifolates are contraindicated in the first trimester of pregnancy. Therefore, ACTs containing sulfadoxine-pyrimethamine are contraindicated during the first trimester of pregnancy.
* There is currently no documented record of the use of artesunate-pyronaridine during the first trimester of pregnancy.
* Continued pharmacovigilance and clinical research, including prospective controlled trials on the efficacy and safety of antimalarial medicines for the treatment of malaria in pregnancy, should be supported   
  and funded.

# Expected benefits

* The adoption of the new WHO recommendation helps to simplify national treatment guidelines for uncomplicated P. falciparum malaria **as all adults, regardless of pregnancy status, can now be treated with AL**. Pregnancy will no longer need separate malaria treatment guidelines in settings where AL is the first line treatment. This will reduce confusion among health care workers about treatment of pregnant women.
* ACTs are faster acting and more effective with longer post-treatment prophylactic effects than quinine. It is expected that adherence, and therefore effectiveness, will be higher with AL than with quinine because the course is shorter, the regimen simpler to administer and better tolerated than quinine.

# Considerations for implementation of the new recommendation

Indication

* The use of AL in the first trimester is recommended only for uncomplicated case management of malaria. AL is not currently recommended for malaria prevention strategies (i.e., intermittent preventive treatment, or mass drug administration, etc.) as the benefit-risk balance is different for uninfected patients which may not directly benefit from treatment and due to the remaining uncertainty of potential rare drug induced adverse pregnancy outcomes.
* Lumefantrine blood concentration on day-7 was reported to be significantly lower in pregnant than non-pregnant woman20; however, current AL dosing guidelines should be followed until dose optimization for pregnant women is determined. Absorption of AL is significantly increased by taking the medicines with fat.20,21

Sourcing of medicine and supply chain management

* Only AL of proven quality should be used. Sources of WHO-prequalified medicines can be found via the following link: <https://extranet.who.int/prequal/content/prequalified-lists/medicines>. WHO has prequalified several finished pharmaceutical products of artemether-lumefantrine with tablet strengths of 80mg/480mg which allow a reduction in the number of tablets per dose for adult patients. The Global Fund List of Pharmaceutical Products compliant with the quality assurance policy is accessible via: [https://www.theglobalfund.org/media/4756/psm\_ productsmalaria\_list\_en.pdf](https://www.theglobalfund.org/media/4756/psm_%20productsmalaria_list_en.pdf). Both lists are regularly updated.
* As AL is already widely procured in settings where it is first line therapy, the additional procurement of AL to treat malaria in the first trimester should have minimal impact on supply chain management of antimalarials.9-12
* For countries where AL is not the recommended first-line treatment or is not available, then artesunate-amodiaquine (ASAQ), artesunate-mefloquine (ASMQ) and dihydroartemisinin-piperaquine (DHA-PPQ) may be used for treatment of uncomplicated malaria in the first trimester of pregnancy.
* The price of ACTs including AL is generally higher than quinine in the private sector. In many countries, malaria treatment in the public sector is provided free of charge to children under five and pregnant women.
* It will be important to ensure stock of oral quinine and clindamycin in case of known allergy to AL or other ACTs.22

Safety monitoring

* Monitoring the safety of antimalarial treatment in pregnancy is important and should continue to provide further reassurance, in particular to gather more data on ACTs other than AL as well as for specific congenital anomalies.15 Malaria endemic countries are urged **to set up active pharmacovigilance surveillance for antimalarial drugs used in the first trimester of pregnancy**. There are several publications on the methods and protocols to assess drug safety in pregnancy in low-middle income countries.23-25 Such active pharmacovigilance surveillance of pregnant women should be widely promoted, and healthcare providers should be encouraged to enroll women treated with antimalarials in pregnancy to enhance participation and recruitment. Research projects and surveillance programmes should be integrated at the country level and countries are encouraged to routinely contribute safety data to this WHO international registry.
* Key considerations for countries collecting safety data on antimalarial use in pregnancy are:
* More data are needed on different ACTs as over 70% of the safety data gathered to date is for AL.
* More data are needed on congenital anomalies, particularly on internal anomalies such as cardiovascular defects. This will require systematic assessment of in-utero exposed newborns by trained healthcare professionals.
* Accurate pregnancy dating and pre-treatment fetal viability will also be needed to expand the cohort of women exposed in the putative embryo-sensitive window period.
* The methodology for reporting pregnancy outcomes including miscarriage and stillbirth needs wider promotion and uptake.26
* Given the relatively common co-occurrence of malaria and HIV, it is important to consider potential drug-drug interactions between antimalarials and antiretroviral treatment regimens.
* Messages about the safety of drugs in pregnancy and the importance of assessment of pregnancy status at the point of care should be promoted to encourage rational drug use in this vulnerable group. This will require some behaviour change communication and addressing social norms around pregnancy.

Strengthening health systems

* National malaria control programmes should ensure inclusion of AL in national malaria control strategies and wide dissemination of clear malaria treatment guidelines based on the WHO recommendation, and ensure this is reflected in relevant guidelines for antenatal care and community healthcare workers in settings where they provide treatment for malaria.
* This change in policy is an opportunity to strengthen national technical working groups focusing on, or including, malaria in pregnancy to improve the quality and coverage of malaria in pregnancy interventions.
* Capacity development to improve healthcare workers’ knowledge is important. Several studies have shown poor health care provider knowledge and poor patient adherence to malaria treatment in pregnancy as recommended in national treatment guidelines12,27; determinants of provider adherence need to be assessed in both the public and private sectors.28
* It will also be important to identify potential barriers to the use of ACTs in the first trimester at the patient/user level and in communities, as well as implementation barriers among health care providers and other stakeholders (including community leaders, programme managers, donors, policy makers and opinion leaders).28

# Rationale for this update

Restriction of the use of ACTs during the first trimester of pregnancy was based on embryo toxicity identified in animal studies6,29 and limited information on human exposures. The previous WHO reviews on the safety of artemisinin antimalarials in the first trimester of pregnancy took place in 2002 and 2006.30,31 At the time of the second consultation, the evidence reviewed was limited to 170 first trimester human exposures from Thailand which was insufficient to assess whether the embryotoxicity observed in animal studies could also occur in humans. Since this initial consultation, several studies have provided additional information on the safety of artemisinin antimalarials in early pregnancy with data on over 1000 pregnancies treated in the first trimester with an artemisinin derivative (see Annex 2). **None of these studies found any evidence of artemisinin teratogenicity or increased risk of pregnancy loss compared to pregnant women exposed to quinine treatment.** In 2015, WHO convened an Evidence Review Group meeting on malaria in pregnancy32 including a review of new evidence from a meta-analysis of safety data from documented human exposures in the first trimester from Asia and Africa (717 artemisinin and 947 quinine) which indicated that ACT exposure in the first trimester of pregnancy does not increase the risk of miscarriage, stillbirths or major congenital anomalies compared to quinine.33 Although the Evidence Review Group and the Malaria Advisory Committee at the time recommended an update to the treatment guidelines to “consider the timely inclusion of ACTs as a first-line therapeutic option for uncomplicated P. falciparum malaria”34, this did not materialise. In 2021, WHO requested an update to the original meta-analysis with any new safety data that has become available since 2015, with the goal to re-review the evidence on the safety of artemisinin used for the treatment of malaria in the first trimester of pregnancy.

In addition to the evidence summarised in the WHO Malaria Guidelines19, WHO is preparing an update of a technical report on the safety of artemisinin and non-artemisinin antimalarials in the first trimester of pregnancy providing a thorough review of the evidence.71

# Comparative data on the treatment of uncomplicated malaria with artemisinin antimalarials and quinine

There are currently no randomized controlled trials comparing the safety and/or efficacy of ACTs and quinine in the first trimester. A comparison of key characteristics of ACTs and quinine is shown in Table 1.

Evidence from clinical trials in non-pregnant adults and second/third trimester pregnancies show that ACTs are more effective than quinine-based therapies for the treatment of uncomplicated malaria.14-16,35 A meta-analysis of four randomised controlled trials from sub-Saharan Africa and Thailand for uncomplicated P. falciparum malaria in the second and third trimesters showed that ACTs were more effective than oral quinine-based therapies with faster parasite clearance, lower PCR-corrected treatment failure rates, lower gametocyte carriage, and higher mean birth weights.14 A recent meta-analysis of 48 efficacy studies confirmed that ACTs had significantly lower risk of treatment failure compared to quinine-based treatments in pregnancy.15 This was confirmed by a recent meta-analysis reporting 2nd and 3rd trimester pregnancies treated with quinine were at 6-fold higher risk of treatment failure compared to those treated with AL.16 ACTs were found to be much better tolerated than quinine, which is associated with cinchonism presenting as tinnitus, nausea, headache and blurred vision. In addition, adherence to ACTs, taken 1 or 2 times daily over 3 days, is expected to be higher than for quinine which has to be taken 3 times daily for 7 days.36

Table Summary comparison of ACTs and Quinine

|  | Artemisinin-based combination therapies | Quinine |
| --- | --- | --- |
| Safety and tolerability | * Common side effects include nausea, vomiting, and diarrhoea, which are also symptoms of malaria itself.37,38 Side effects are generally mild; severe adverse events are rare. * There have been concerns for teratogenicity in early pregnancy due to animal embryo-toxicity (in rats, rabbits and monkeys) of artemisinin as a class at low dose.29 * ACT partner drugs:   SP, an antifolate, is contraindicated in the first trimester,  lumefantrine, amodiaquine,39 and piperaquine are considered likely to be safe,  mefloquine is approved for use in the first trimester (US and UK)40  data of pyronaridine use in any trimester of pregnancy are limited, although no safety signals were reported with pyronaridine in pre-clinical studies.40   * Pregnancy registries found no increase in the risk of pregnancy loss (miscarriage or stillbirth), or major congenital anomalies associated with artemisinin exposures early in pregnancy compared to quinine.33,41 | * Poor tolerability; nausea, vomiting, and cinchonism are common but mild and resolve relatively rapidly upon stopping drug.35,36 Hypoglycaemia is a common side effect, particularly in pregnant women, and can be mild or severe. Serious adverse events are rare and include skin eruptions, asthma, thrombocytopaenia, hepatic injury, psychosis, cytopenia, and haemolytic-uremic syndrome.42 * Recommended in pregnancy although evidence is mostly historical (no trial data in 1st trimester). * Animal studies reported that quinine affected the development of the brain and inner ear in the rabbit, chinchilla, and guinea pig at dose close to or below the therapeutic dose for malaria. Quinine caused embryonic deaths in the rabbit, mouse, chinchilla, and dog at relatively low dose.40 |
| Efficacy | * No randomized controlled trials have been performed using either ACTs or quinine for treatment of malaria in the first trimester of pregnancy. * ACTs have better efficacy than quinine in 2nd/3rd trimester of pregnancy and non-pregnant populations for uncomplicated malaria.14,15 * Longer duration of post-treatment prophylaxis conferred by ACTs is another important benefit in pregnancy as they prevent new infections for several weeks, whereas quinine has no post-treatment prophylactic effect due to its short half-life.17,18 * Parenteral artesunate treatment is superior to quinine in the treatment of severe malaria.2,43, 44 | |
| Drug resistance | * Emergence of partial-resistance to artemisinins in southeast Asia45,46 and parts of sub-Saharan Africa (Uganda, Rwanda and Eritrea).47 * Treatment failure <10% for AL and AS-AQ in some areas of Africa.15,46 | * Quinine resistance documented in southeast Asia.48 * Limited evidence of quinine resistance in Africa.35,49 |
| Administration /patient adherence | * 2 times daily for 3 days * AL best taken with fat (meal) to ensure adequate lumefantrine absorption20 * Adherence varies by setting and population50,51 | * 3 times daily for 7 days * Adherence is low due to poor tolerability and long treatment regimen36 * Poor adherence to recommended use with clindamycin |
| Cost | * Prices of ACTs have decreased substantially in recent years and are comparable to those for quinine.7,8 | * Quinine is inexpensive, but the price of the combination of quinine and clindamycin is high. |
| Availability | * Fixed-dose ACTs are widely available and recommended as first line therapy for treatment of uncomplicated malaria in most malaria endemic countries. Coverage in both public and private sector has increased. | * Quinine has been widely available, although use of combination therapy with clindamycin is rare, particularly in Africa. * In the private sector, multiple quinine brands, with different salts and tablet strengths, makes the administration of correct treatment doses difficult. * There have been reports of limited availability and supply of quinine in the public sector in parts of Africa as it is solely used for 1st trimester patients. |

A recent updated systematic review and individual-patient data (IPD) meta-analysis of seven prospective studies (including 12 cohorts) found no increase in the risk of adverse pregnancy outcomes (composite including miscarriage, stillbirth or major congenital anomalies) associated with artemisinin exposures in the first trimester of pregnancy (n=736) compared to non-artemisinin based exposures (n=1074 [85% were quinine], adjusted Hazard Ratio (aHR: 0·71, 95% confidence interval 0·49-1·03) (Table 2).13 Fourteen studies were identified reporting artemisinin exposure in the first trimester, of which seven were eligible and all included in the IPD analysis; five from sub-Saharan Africa and one from the Shoklo Malaria Research Unit (SMRU) on the Thailand-Myanmar border.

AL was the only ACT with sufficient data for a sub-group analysis. The risk of adverse pregnancy outcomes was lower with AL than with oral quinine in the first trimester (25/524 [4·8%] vs 84/915 [9·2%], aHR=0·58, 0·36-0·92). Similar results were seen for the individual components: miscarriage (AL=15/465] vs Quinine=68/915, aHR=0·67, 0·37-1·23), stillbirth (AL=10/488 vs quinine=12/592, aHR=0·53, 0·22-1·24). There were no major congenital anomalies in the AL exposed group and the estimated upper limit of prevalence of major congenital anomalies was similar to that observed in the quinine or unexposed group. The corresponding risk of adverse pregnancy outcome in analysis restricted to exposure to artemisinins during the putative embryo-sensitive period (6–12 weeks of gestation) was aHR = 0·95 (0·63–1·45).

Table . Summary of effect estimates from the meta-analysis data reviewed by WHO: Adverse pregnancy outcomes in women treated with antimalarials in the first trimester.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Outcomes | Number of participants | | Adjusted Hazard ratio (95% CI) | Risk difference (95% CI) |
|
|  | **non-ABT#** | **ABT\*** |  |  |
| **Composite** | 96/1074 | 42/736 | 0.71 (0.49,1.03) | -25 (-45, 3) |
| **Miscarriage** | 76/1070 | 27/669 | 0.74 (0.47,1.17) | -18 (-37, 12) |
| **Stillbirth** | 12/743 | 13/646 | 0.71 (0.32, 1.57) | -5 (-11, 9) |
| **Fetal loss** | 88/1074 | 40/736 | 0.70 (0.47, 1.02) | -24 (-43, 2) |
| **Major congenital anomalies** | 8/1074 | 2/736 | 0.60 (0.13, 2.87) | -3 (-6, 14) |
|  | **Quinine** | **AL** |  |  |
| **Composite** | 84/915 | 25/524 | 0.58 (0.36-0.92) | -37 (-58, -7) |
| **Miscarriage** | 68/913 | 15/464 | 0.67 (0.37-1.23) | -24 (-46, 16) |
| **Stillbirth** | 12/590 | 10/488 | 0.53 (0.22-1.24) | -10 (-16, 5) |
| **Fetal loss** | 80/915 | 25/524 | 0.56 (0.35-0.90) | -37 (-56, -8) |
| **Major congenital anomalies** | 4/915 | 0/524 | NA | NA |
| Acronyms: ABT, artemisinin-based treatment; non-ABT, non-artemisinin-based treatment; AL, artemether-lumefantrine.  \*ABT included in the analysis: 637 ACT (525 AL, 32 ASAQ, 58 ASMQ, 19 DHA-PPQ, 3 artesunate+atovaquone-proguanil), 95 AS (with and without clindamycin), 5 parenteral artesunate.  #Non-ABT included in the analysis: 917 oral quinine (715 quinine monotherapy, 202 quinine+clindamycin), 9 parenteral quinine, 147 chloroquine, 1 mefloquine, 1 atovaquone-proguanil, 1 quinine+mefloquine | | | | |

# Annex 1. Frequently Asked Questions (FAQs)

Which antimalarials are considered safe in the first trimester of pregnancy?

|  |  |  |
| --- | --- | --- |
| Antimalarials considered safe in first trimester | Antimalarials with limited data on use in first trimester  of pregnancy | Antimalarials contraindicated in first trimester |
| * Chloroquine * Amodiaquine * Quinine * Clindamycin * Mefloquine * Artemether-lumefantrine | * Dihydroartemisinin-piperaquine\* * Mefloquine-artesunate\* * Amodiaquine-artesunate\* * Pyronaridine-artesunate¥ | * Sulfadoxine-pyrimethamine# * Trimethoprim-sulfamethoxazole# * Primaquine * Tafenoquine * Doxycycline * Tetracycline |
| * \*Can be prescribed in 1st trimester if artemether-lumefantrine is not available. * ¥ Not currently recommended in the 1st trimester due to very limited data on human exposures in the 1st trimester (see annex 2). * # Contra-indicated in first trimester but approved for use in 2nd and 3rd trimesters. | | |

For more details on pre-clinical and clinical data on these antimalarial in the first trimester see WHO report “Safety of artemisinins and non-artemisinin antimalarials in the first trimester of pregnancy: review of the evidence”.71

Can AL be used for the treatment of malaria infections with other Plasmodium species including P. vivax?

The current WHO guidelines for malaria treatment recommend treating adults and children with uncomplicated P. vivax, P. ovale, P. malariae*or*P. knowlesi malaria with either an ACT or chloroquine (in areas with chloroquine-susceptible infections, see section 5.2.1.519). The same recommendations apply for treatment with ACTs in the first trimester of pregnancy, namely to treat pregnant women with uncomplicated malaria with AL during the first trimester. If AL is not a recommended ACT for uncomplicated malaria or is not available, other ACTs may be used except artesunate + sulfadoxine-pyrimethamine or pyronaridine-artesunate.

Why are there no randomized clinical trials of antimalarials in the first trimester?

Clinical trials that assess the safety and efficacy of new drugs, including antimalarials, typically exclude pregnant women due to fear of harm to the mother and her fetus. The period of particular concern is the first trimester (gestational age <13 weeks) when organogenesis occurs, and the fetus is most vulnerable to potential developmental toxicity. Recruiting women this early in pregnancy is ethically and practically challenging. Therefore, evidence for treating pregnant women in early pregnancy is scarce and to date has been based on observational studies from inadvertent exposure rather than interventional clinical trials. However, it has taken over 20 years to generate robust evidence for AL from observational studies. There is increasing recognition that data gaps on the safe use of medicines in pregnant women generally need to be addressed ethically and rapidly. In addition, there is growing international support for trial designs that are more inclusive of pregnant participants. It is important to assess the options for conducting clinical trials of antimalarial treatments in the first trimester to enable these pregnant women to promptly access the best treatments.

What is the level of risk associated with artemisinin that can be excluded with the current evidence?

Level of risk detectable for miscarriage and stillbirth

A recent meta-analysis of seven prospective cohort studies found no increase in the risk of adverse pregnancy outcomes (including miscarriage, stillbirth or major congenital anomalies) associated with artemisinin exposures early in pregnancy (Table 2).13 This study could exclude an increase in miscarriage (spontaneous fetal loss before 28 weeks gestation) risk greater than 1.45-fold (as suggested by the upper limit of the confidence interval for the most conservative estimate looking at the postulated embryo-sensitive period for artemisinin and a 3.18-fold or greater increase in the risk for stillbirth (fetal loss at or after 28 weeks gestation).

Level of risk detectable for major congenital anomalies

The meta-analysis of observational studies showed no difference in the prevalence of major congenital anomalies (defined as any structural anomaly deemed to be of surgical, medical, or cosmetic importance at birth, detected by surface examination of livebirths by trained birth attendants) between first trimester exposures to artemisinin-based treatments (ABTs) compared to non-ABTs (aHR 0·60, 95%CI 0·13–2·87) or those unexposed to antimalarials in the first trimester (aHR 0·99, 95%CI 0·24–4·03). No major congenital anomalies were observed in the AL-exposed group (0/482), and the 95% CI estimates suggest that the prevalence of major congenital anomalies would lie between 0% and 0·79%. This upper confidence limit is similar to the 0·69% background rate of major congenital anomalies detected at birth by surface examination in the group unexposed to antimalarials (182/26270, 95% CI 0·60–0·80) and the in the quinine-exposed group (4/545, 0·74%, 95%CI 0·29–1·88). Neither limb deformities nor congenital heart defects, which were reported in animals, were observed in ABT-exposed pregnancies, although cardiac auscultation of newborns was systematically assessed only in one study and other studies did not systematically screen for heart defects. Major congenital anomalies observed in ABT-exposed pregnancies included a cleft lip and palate, a case of bilateral syndactyly and one case of imperforated anus. This study could exclude an increased risk of major congenital anomalies greater than 3.49-fold (as suggested by the upper limit of the confidence interval for the most conservative estimate looking at the postulated embryo-sensitive period for artemisinin.

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Author** | **Country** | **Publication Year** | **Number of confirmed first trimester exposures** | **AL** | **DHA - PPQ** | **AS - AQ** | **AS - MQ** | **AAP** | **AS - SP** | **PYR - AS** | **AS** | **AS (IV/IM)** |
| McGready59,60 | Thai-Myanmar Border | Published and Unpublished between 2000-2020 | 351 | 28 | 28 | 0 | 65 | 3 |  |  | 228 | 10 |
| Deen61 | The Gambia | 2001 | 77 |  |  |  |  |  | 77 |  |  |  |
| Adam62 | Sudan | 2001 | 1 |  |  |  |  |  |  |  |  | 1 |
| Adam63 | Sudan | 2009 | 62 | 3 |  |  |  |  | 11 |  |  | 48 |
| Dellicour64 | Senegal | 2013 | 7 |  |  | 7 |  |  |  |  |  |  |
| Manyando65 | Zambia | 2010 | 156 | 156 |  |  |  |  |  |  |  |  |
| Rulisa66 | Rwanda | 2012 | 96 | 96 |  |  |  |  |  |  |  |  |
| Mosha10 | Tanzania | 2014 | 168 | 168 |  |  |  |  |  |  |  |  |
| Poespoprodjo67 | Indonesia | 2014 | 18 |  | 13 |  |  |  |  |  |  | 10 |
| Dellicour9,25 | Kenya | 2017 | 85 | 85 |  |  |  |  |  |  |  |  |
| Sevene25 | Mozambique | 2017 | 21 | 21 |  |  |  |  |  |  |  |  |
| Tinto25 | Burkina Faso | 2017 | 41 | 1 |  | 40 |  |  |  |  |  |  |
| Ahmed68 | Indonesia | Unpublished | 204 |  | 204 |  |  |  |  |  |  |  |
| Gomes24 | Kenya, Ghana, Tanzania, Uganda | 2022 | 15 | 10 | 2 | 2 |  |  |  |  |  | 1 |
| Rouamba69 | Burkina Faso | 2022 | 19 | 7 | 5 | 5 |  |  |  |  | 2 |  |
| Rouamba70 | Burkina Faso | 2020 | 13 |  |  | 13 |  |  |  |  |  |  |
| Lutete 58 | DRC | 2021 | 6 |  |  |  |  |  |  | 6 |  |  |
| **Total** | **13** | **2000-22** | **1340** | **575** | **252** | **67** | **65** | **3** | **88** | **6** | **230** | **70** |
| Acronyms: AAP, artesunate+atovaquone-proguanil; AL, artemether-lumefantrine; AS-AQ, artesunate-amodiaquine; AS, artesunate; AS-SP, artesunate + sulfadoxine-pyrimethamine; DHA-PPQ, dihydroartemisinin-piperaquine; DRC, Democratic Republic of the Congo IM, intramuscular; IV, intravenous; AS-MQ: artesunate-mefloquine, PYR-AS: pyronaridine-artesunate. | | | | | | | | | | | | |

# Annex 2. Number of confirmed exposed pregnancies for each artemisinin treatment type

# References

1. Rogerson SJ, Meshnick S. Malaria in Pregnancy: Late Consequences of Early Infections. J Infect Dis 2019; 220(9): 1396-8.
2. WHO. Guidelines for the treatment of malaria. Third edition. Geneva, Switzerland: World Health Organization, 2015.
3. Peters PJ, Thigpen MC, Parise ME, Newman RD. Safety and toxicity of sulfadoxine/pyrimethamine: implications for malaria prevention in pregnancy using intermittent preventive treatment. Drug safety 2007; 30(6): 481-501.
4. WHO. A strategic framework for malaria prevention and control during pregnancy in the African region. Brazzaville, World Health Organization, Regional Office for Africa

http://whqlibdoc.who.int/afro/2004/AFR\_MAL\_04.01.pdf, 2004.

1. Clark RL. Embryotoxicity of the artemisinin antimalarials and potential consequences for use in women in the first trimester. *Reproductive toxicology (Elmsford, NY)* 2009; **28**(3): 285-96.
2. Clark RL. Teratogen update: Malaria in pregnancy and the use of antimalarial drugs in the first trimester. *Birth Defects Res* 2020; **112**(18): 1403-49.
3. Tougher S, Group AC, Ye Y, et al. Effect of the Affordable Medicines Facility--malaria (AMFm) on the availability, price, and market share of quality-assured artemisinin-based combination therapies in seven countries: a before-and-after analysis of outlet survey data. *Lancet* 2012; **380**(9857): 1916-26.
4. Group A, Tougher S, Hanson K, Goodman C. What happened to anti-malarial markets after the Affordable Medicines Facility-malaria pilot? Trends in ACT availability, price and market share from five African countries under continuation of the private sector co-payment mechanism. *Malar J* 2017; **16**(1): 173.
5. Dellicour S, Desai M, Aol G, et al. Risks of miscarriage and inadvertent exposure to artemisinin derivatives in the first trimester of pregnancy: a prospective cohort study in western Kenya. *Malar J* 2015; **14**(1): 461.
6. Mosha D, Mazuguni F, Mrema S, Sevene E, Abdulla S, Genton B. Safety of artemether-lumefantrine exposure in first trimester of pregnancy: an observational cohort. *Malar J* 2014; **13**: 197.
7. Sangare LR, Weiss NS, Brentlinger PE, et al. Patterns of anti-malarial drug treatment among pregnant women in Uganda. *Malar J* 2011; **10**: 152.
8. Riley C, Dellicour S, Ouma P, et al. Knowledge and Adherence to the National Guidelines for Malaria Case Management in Pregnancy among Healthcare Providers and Drug Outlet Dispensers in Rural, Western Kenya. *PloS one* 2016; **11**(1): e0145616.
9. Saito M, McGready R, Tinto H, et al. First-trimester treatment with artemisinin derivatives versus non-artemisinin antimalarials and the risk of adverse pregnancy outcomes in Africa and Asia: Updated individual patient data meta-analysis. *The Lancet* 2023; **401**(10371):118-130.
10. Burger RJ, van Eijk AM, Bussink M, Hill J, Ter Kuile FO. Artemisinin-Based Combination Therapy Versus Quinine or Other Combinations for Treatment of Uncomplicated Plasmodium falciparum Malaria in the Second and Third Trimester of Pregnancy: A Systematic Review and Meta-Analysis. *Open forum infectious diseases* 2016; **3**(1): ofv170.
11. Saito M, Gilder ME, Nosten F, McGready R, Guerin PJ. Systematic literature review and meta-analysis of the efficacy of artemisinin-based and quinine-based treatments for uncomplicated falciparum malaria in pregnancy: methodological challenges. *Malar J* 2017; **16**(1): 488.
12. Saito M, Mansoor R, Kennon K, et al. Efficacy and tolerability of artemisinin-based and quinine-based treatments for uncomplicated falciparum malaria in pregnancy: a systematic review and individual patient data meta-analysis. *Lancet Infect Dis* 2020; **20**(8): 943-52.
13. World Health Organization. Guidelines for the treatment of malaria. Third edition. Geneva: WHO Press; 2015.
14. Bretscher MT, Dahal P, Griffin J, et al. The duration of chemoprophylaxis against malaria after treatment with artesunate-amodiaquine and artemether-lumefantrine and the effects of pfmdr1 86Y and pfcrt 76T: a meta-analysis of individual patient data. *BMC Medicine* 2020; **18**(1): 47.
15. WHO. WHO Guidelines for malaria, 25 November 2022. Geneva, 2022.
16. Kloprogge F, Workman L, Borrmann S, et al. Artemether-lumefantrine dosing for malaria treatment in young children and pregnant women: A pharmacokinetic-pharmacodynamic meta-analysis. *PLoS Med* 2018; **15**(6): e1002579.
17. Ashley EA, Stepniewska K, Lindegardh N, et al. How much fat is necessary to optimize lumefantrine oral bioavailability? *Trop Med Int Health* 2007; **12**(2): 195-200.
18. Leonardi E, Gilvary G, White NJ, Nosten F. Severe allergic reactions to oral artesunate: a report of two cases. *Trans R Soc Trop Med Hyg* 2001; **95**(2): 182-3.
19. Dellicour S, ter Kuile FO, Stergachis A. Pregnancy exposure registries for assessing antimalarial drug safety in pregnancy in malaria-endemic countries. *PLoS Med* 2008; **5**(9): e187.
20. Mehta U, Clerk C, Allen E, et al. Protocol for a drugs exposure pregnancy registry for implementation in resource-limited settings. *BMC pregnancy and childbirth* 2012; **12**: 89.
21. Tinto H, Sevene E, Dellicour S, et al. Assessment of the safety of antimalarial drug use during early pregnancy (ASAP): protocol for a multicenter prospective cohort study in Burkina Faso, Kenya and Mozambique. *Reproductive health* 2015; **12**: 112.
22. Saito M, Gilder ME, Nosten F, Guerin PJ, McGready R. Methodology of assessment and reporting of safety in anti-malarial treatment efficacy studies of uncomplicated falciparum malaria in pregnancy: a systematic literature review. *Malar J* 2017; **16**(1): 491.
23. Sangaré L, Weiss N, Brentlinger P, et al. Patterns of antimalarial drug treatment among pregnant women in Uganda. *Malaria Journal* 2011; **10**: 152.
24. The SURE Collaboration. SURE Guides for Preparing and Using Evidence-Based Policy Briefs, 2011.
25. Clark RL. Safety of treating malaria with artemisinin-based combination therapy in the first trimester of pregnancy. *Reproductive toxicology (Elmsford, NY)* 2022; **111**: 204-10.
26. WHO, TDR. Assessment of the safety of artemisinin compounds in pregnancy: report of two joint informal consultations convened in 2006. Geneva: WHO, 2007.
27. WHO. Assessment of the safety of artemisinin compounds in pregnancy: report of two joint informal consultations convened in 2002. Geneva, Switzerland: World Health Organization, 2003.
28. WHO. Malaria in pregnancy. WHO Evidence Review Group meeting report, WHO Headquarters, Geneva 13– 16 July 2015. Geneva, Switzerland: WHO Headquarters, 2015.
29. Dellicour S, Sevene E, McGready R, et al. First-trimester artemisinin derivatives and quinine treatments and the risk of adverse pregnancy outcomes in Africa and Asia: A meta-analysis of observational studies. *PLoS Med* 2017; **14**(5): e1002290.
30. WHO. Recommendations on intermittent screening and treatment in pregnancy and the safety of ACTs in the first trimester. Geneva, Switzerland: World Health Organization; 2015.
31. Achan J, Talisuna AO, Erhart A, et al. Quinine, an old anti-malarial drug in a modern world: role in the treatment of malaria. *Malar J* 2011; **10**: 144.
32. Yeka A, Achan J, D'Alessandro U, Talisuna AO. Quinine monotherapy for treating uncomplicated malaria in the era of artemisinin-based combination therapy: an appropriate public health policy? *Lancet Infect Dis* 2009; **9**(7): 448-52.
33. Nosten F, White NJ. Artemisinin-based combination treatment of falciparum malaria. *The American journal of tropical medicine and hygiene* 2007; **77**(6 Suppl): 181-92.
34. Price R, van Vugt M, Phaipun L, et al. Adverse effects in patients with acute falciparum malaria treated with artemisinin derivatives. *The American journal of tropical medicine and hygiene* 1999; **60**(4): 547-55.
35. Tagbor HK, Chandramohan D, Greenwood B. The safety of amodiaquine use in pregnant women. *Expert Opin Drug Saf* 2007; **6**(6): 631-5.
36. Clark RL. Animal Embryotoxicity Studies of Key Non-Artemisinin Antimalarials and Use in Women in the First Trimester. *Birth Defects Res* 2017; **109**: 1075-126.
37. Saito M, McGready R, Tinto H, et al. Pregnancy outcomes after first-trimester treatment with artemisinin derivatives versus non-artemisinin antimalarials: a systematic review and individual patient data meta-analysis. *Lancet* 2023; **401**(10371): 118-30.
38. Looareesuwan S, Phillips RE, White NJ, et al. Quinine and severe falciparum malaria in late pregnancy. *Lancet* 1985; **2**(8445): 4-8.
39. D'Alessandro U, Hill J, Tarning J, et al. Treatment of uncomplicated and severe malaria during pregnancy. *Lancet Infect Dis* 2018.
40. Dondorp AM, Fanello CI, Hendriksen IC, et al. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. *Lancet* 2010; **376**(9753): 1647-57.
41. Ashley EA, Dhorda M, Fairhurst RM, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. *N Engl J Med* 2014; **371**(5): 411-23.
42. WHO. World malaria report 2017. Geneva: World Health Organization, 2017.
43. WHO. Malaria: Artemisinin resistance Q & A. 2022. <https://www.who.int/news-room/questions-and-answers/item/artemisinin-resistance> (accessed 21 November 2022.
44. Pukrittayakamee S, Supanaranond W, Looareesuwan S, Vanijanonta S, White NJ. Quinine in severe falciparum malaria: evidence of declining efficacy in Thailand. *Trans R Soc Trop Med Hyg* 1994; **88**(3): 324-7.
45. Pradines B, Pistone T, Ezzedine K, et al. Quinine-resistant malaria in traveler returning from Senegal, 2007. *Emerg Infect Dis* 2010; **16**(3): 546-8.
46. Yakasai AM, Hamza M, Dalhat MM, et al. Adherence to Artemisinin-Based Combination Therapy for the Treatment of Uncomplicated Malaria: A Systematic Review and Meta-Analysis. *J Trop Med* 2015; **2015**: 189232.
47. Banek K, Lalani M, Staedke SG, Chandramohan D. Adherence to artemisinin-based combination therapy for the treatment of malaria: a systematic review of the evidence. *Malar J* 2014; **13**: 7.
48. Gonzalez R, Mombo-Ngoma G, Ouedraogo S, et al. Intermittent preventive treatment of malaria in pregnancy with mefloquine in HIV-negative women: a multicentre randomized controlled trial. *PLoS Med* 2014; **11**(9): e1001733.
49. Gonzalez R, Desai M, Macete E, et al. Intermittent preventive treatment of malaria in pregnancy with mefloquine in HIV-infected women receiving cotrimoxazole prophylaxis: a multicenter randomized placebo-controlled trial. *PLoS Med* 2014; **11**(9): e1001735.
50. Gonzalez R, Pons-Duran C, Piqueras M, Aponte JJ, Ter Kuile FO, Menendez C. Mefloquine for preventing malaria in pregnant women. *The Cochrane database of systematic reviews* 2018; **3**: Cd011444.
51. Group PS, Pekyi D, Ampromfi AA, et al. Four Artemisinin-Based Treatments in African Pregnant Women with Malaria. *N Engl J Med* 2016; **374**(10): 913-27.
52. Hernandez-Diaz S, Werler MM, Walker AM, Mitchell AA. Folic acid antagonists during pregnancy and the risk of birth defects. *N Engl J Med* 2000; **343**(22): 1608-14.
53. Phillips-Howard PA, Wood D. The safety of antimalarial drugs in pregnancy. *Drug safety* 1996; **14**(3): 131-45.
54. Tona Lutete G, Mombo-Ngoma G, Assi SB, et al. Pyronaridine-artesunate real-world safety, tolerability, and effectiveness in malaria patients in 5 African countries: A single-arm, open-label, cohort event monitoring study. *PLoS Med* 2021; **18**(6): e1003669.
55. McGready R, Lee SJ, Wiladphaingern J, et al. Adverse effects of falciparum and vivax malaria and the safety of antimalarial treatment in early pregnancy: a population-based study. *Lancet Infect Dis* 2012; **12**(5): 388-96.
56. Moore KA, Simpson JA, Paw MK, et al. Safety of artemisinins in first trimester of prospectively followed pregnancies: an observational study. *Lancet Infect Dis* 2016; **16**(5): 576-83.
57. Deen JL, von Seidlein L, Pinder M, Walraven GE, Greenwood BM. The safety of the combination artesunate and pyrimethamine-sulfadoxine given during pregnancy. *Trans R Soc Trop Med Hyg* 2001; **95**(4): 424-8.
58. Adam I, Elwasila E, Mohammed Ali DA, Elansari E, Elbashir MI. Artemether in the treatment of falciparum malaria during pregnancy in eastern Sudan. *Trans R Soc Trop Med Hyg* 2004; **98**(9): 509-13.
59. Adam I, Elhassan EM, Omer EM, Abdulla MA, Mahgoub HM, Adam GK. Safety of artemisinins during early pregnancy, assessed in 62 Sudanese women. *Annals of tropical medicine and parasitology* 2009; **103**(3): 205-10.
60. Dellicour S, Brasseur P, Thorn P, et al. Probabilistic record linkage for monitoring the safety of artemisinin-based combination therapy in the first trimester of pregnancy in Senegal. *Drug safety* 2013; **36**(7): 505-13.
61. Manyando C, Mkandawire R, Puma L, et al. Safety of artemether-lumefantrine in pregnant women with malaria: results of a prospective cohort study in Zambia. *Malar J* 2010; **9**: 249.
62. Rulisa S, Kaligirwa N, Agaba S, Karema C, Mens PF, de Vries PJ. Pharmacovigilance of artemether-lumefantrine in pregnant women followed until delivery in Rwanda. *Malar J* 2012; **11**: 225.
63. Poespoprodjo JR, Fobia W, Kenangalem E, et al. Dihydroartemisinin-piperaquine treatment of multidrug resistant falciparum and vivax malaria in pregnancy. *PloS one* 2014; **9**(1): e84976.
64. Ahmed R. Pregnancy outcomes in women exposed to dihydroartemisinin-piperaquine during first trimester of pregnancy in Indonesia- Final Study Report. Unpublished, 2019.
65. Rouamba T, Valea I, Bognini JD, et al. Safety Profile of Drug Use During Pregnancy at Peripheral Health Centres in Burkina Faso: A Prospective Observational Cohort Study. *Drugs Real World Outcomes* 2018; **5**(3): 193-206.
66. Rouamba T, Sondo P, Derra K, et al. Optimal Approach and Strategies to Strengthen Pharmacovigilance in Sub-Saharan Africa: A Cohort Study of Patients Treated with First-Line Artemisinin-Based Combination Therapies in the Nanoro Health and Demographic Surveillance System, Burkina Faso. Drug Des Devel Ther 2020; 14: 1507-21.
67. Recht J., Clark R., González R. and Dellicour S. Safety of artemisinin and non-artemisinin antimalarials in the first trimester of pregnancy: Review of evidence. WHO Technical Report. In Press.

1. https://www.who.int/publications/i/item/guidelines-for-malaria [↑](#footnote-ref-2)